Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder

Abstract

The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.

What is claimed is: 
     
       1. A method of treating attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1 , R 2  and R 3  are independently selected from the group consisting of H, cyano, hydroxyl, halo, alkoxy, nitro, C 1-6  alkyl, and carboxy; 
 R 4  is selected from the group consisting of H and C 1-6  alkyl; 
 R 5  is selected from the group consisting of H, C 1-6  alkyl, and substituted C 1-6  alkyl; and, 
 n is 2; 
 
       a pharmaceutically acceptable salt or solvate thereof, and any mixtures thereof. 
     
     
       2. The method of  claim 1 , wherein administration of the compound improves sustained attention in the subject. 
     
     
       3. The method of  claim 1 , wherein in formula (I) R 1 , R 2  and R 3  are independently selected from the group consisting of H, halo, alkoxy, and C 1-6  alkyl. 
     
     
       4. The method of  claim 1 , wherein in formula (I) R 5  is selected from the group consisting of H, and C 1-6  alkyl. 
     
     
       5. The method of  claim 1 , wherein the at least one compound is selected from the group consisting of: 2-amino-4-(2-chlorophenyl)butan-1-ol; 2-(3-aminohexyl)phenol; 4-(2-chlorophenyl)-2-methylamino-butane; 4-(2-chlorophenyl)-butan-2-amine; 4-(2-fluorophenyl)butan-2-amine; 4-(2-bromophenyl)butan-2-amine; 4-(2-iodophenyl)butan-2-amine; 4-(2-methoxyphenyl)butan-2-amine; 2-(3-aminobutyl)phenol; 3-(3,4-diethoxyphenyl)propan-1-amine; 4-(4-chlorophenyl)butan-2-amine; 4-(4-methoxyphenyl)butan-2-amine; a pharmaceutically acceptable salt or solvate, and mixtures thereof. 
     
     
       6. The method of  claim 1 , wherein the composition further comprises at least one drug selected from the group consisting of methylphenidate, dextroamphetamine, dextroamphetamine-amphetamine, lisdexamfetamine, an additional compound that is used to treat ADHD, antidepressant, clonidine, guanfacine, and a salt or solvate thereof. 
     
     
       7. The method of  claim 1 , wherein the subject is human. 
     
     
       8. A method of treating dementia associated with a neurodegenerative disease in a subject in need thereof, wherein the neurodegenerative disease comprises at least one selected from the group consisting of Alzheimer's Disease (AD), Huntington's Disease, transmissible spongiform encephalopathies (TSEs), chronic traumatic encephalopathy (CTE) resulting from repeated traumatic brain injuries, and amyotrophic lateral sclerosis (ALS), the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1 , R 2  and R 3  are independently selected from the group consisting of H, cyano, hydroxyl, halo, alkoxy, nitro, C 1-6  alkyl, and carboxy; 
 R 4  is selected from the group consisting of H and C 1-6  alkyl; 
 R 5  is selected from the group consisting of H, C 1-6  alkyl, and substituted C 1-6  alkyl; and, 
 n is 2; 
 
       a pharmaceutically acceptable salt or solvate thereof, and any mixtures thereof. 
     
     
       9. The method of  claim 8 , wherein in formula (I) R 1 , R 2  and R 3  are independently selected from the group consisting of H, halo, alkoxy, and C 1-6  alkyl. 
     
     
       10. The method of  claim 8 , wherein in formula (I) R 5  is selected from the group consisting of H and C 1-6  alkyl. 
     
     
       11. The method of  claim 8 , wherein the at least one compound is selected from the group consisting of: 2-amino-4-(2-chlorophenyl)butan-1-ol; 2-(3-aminohexyl) phenol; 4-(2-chlorophenyl)-2-methylamino-butane; 4-(2-chlorophenyl)-butan-2-amine; 4-(2-fluorophenyl)butan-2-amine; 4-(2-bromophenyl)butan-2-amine; 4-(2-iodophenyl)butan-2-amine; 4-(2-methoxyphenyl)butan-2-amine; 2-(3-aminobutyl) phenol; 3-(3,4-diethoxyphenyl)propan-1-amine; 4-(4-chlorophenyl)butan-2-amine; 4-(4-methoxyphenyl)butan-2-amine; a pharmaceutically acceptable salt thereof, and any mixtures thereof. 
     
     
       12. The method of  claim 8 , wherein the composition further comprises at least one drug selected from the group consisting of methylphenidate, dextroamphetamine, dextroamphetamine-amphetamine, lisdexamfetamine, an additional compound that is used to treat ADHD, antidepressants, clonidine, guanfacine, and a salt or solvate thereof. 
     
     
       13. The method of  claim 8 , wherein the subject is human.